Trials / Completed
CompletedNCT06880848
Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China
A Prospective, Open-Label, Single-Arm, Multi-Center, Phase IV Efficacy and Safety Study of Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 160 (actual)
- Sponsor
- Jemincare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase IV, single arm, multicenter study designed to evaluate the efficacy and safety profile of Sonidegib in chinese participants with locally advanced basal cell carcinoma (laBCC) who are not amenable to radiation therapy, curative surgery or other local therapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sonidegib Phosphate Capsules | Sonidegib should be taken 1 hour before or 2 hours after a breakfast |
Timeline
- Start date
- 2023-06-21
- Primary completion
- 2025-08-26
- Completion
- 2025-08-26
- First posted
- 2025-03-18
- Last updated
- 2025-09-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06880848. Inclusion in this directory is not an endorsement.